Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.30 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6898456 | 1.00 | CES2 (0.33) | CES2CES1EGFRSRCLMNA | |
| SCHEMBL2904167 | 0.86 | MAPT (0.40) | CES2CES1EGFRLMNAMAPT | |
| SCHEMBL25430666 | 0.75 | MAPT (0.46) | LMNAMAPTALDH1A1IDO1GAA | |
| SCHEMBL38659796 | 0.75 | MAPK10 (0.36) | LMNAMAPTALDH1A1IDO1GAA | |
| SCHEMBL19909186 | 0.72 | RAB9A (0.34) | MAPTALDH1A1IDO1GAARAB9A | |
| SCHEMBL8960968 | 0.72 | RAB9A (0.34) | LMNAMAPTALDH1A1GAARAB9A | |
| SCHEMBL24289554 | 0.70 | — | — | |
| SCHEMBL3669787 | 0.70 | EGFR (0.42) | EGFRMAPTALDH1A1GAARAB9A | |
| SCHEMBL28214746 | 0.69 | CREBBP (0.38) | MAPTGAARAB9ACREBBP | |
| SCHEMBL31582338 | 0.69 | ALDH1A1 (0.35) | LMNAMAPTALDH1A1RAB9ABRPF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124198-A1 | ANTIVIRAL PYRAZOLOPYRIDINONE COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-05-07 | — | — | US | claimed |
| US-20260124198-A1 | ANTIVIRAL PYRAZOLOPYRIDINONE COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124198-A1 | ANTIVIRAL PYRAZOLOPYRIDINONE COMPOUNDS | ZC3HAV1, CCR1, CCR6 | CES2 493/4885CES1 253/4885EGFR 648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.